APA (7th ed.) Citation

MM, E., WM, E., AA, A. E., WR, S., A, A., ST, A., . . . M, A. (2022). 2-Arylquinolines as novel anticancer agents with dual EGFR/FAK kinase inhibitory activity: Synthesis, biological evaluation, and molecular modelling insights. Journal of enzyme inhibition and medicinal chemistry, 37(1), 349. https://doi.org/10.1080/14756366.2021.2015344

Chicago Style (17th ed.) Citation

MM, Elbadawi, et al. "2-Arylquinolines as Novel Anticancer Agents with Dual EGFR/FAK Kinase Inhibitory Activity: Synthesis, Biological Evaluation, and Molecular Modelling Insights." Journal of Enzyme Inhibition and Medicinal Chemistry 37, no. 1 (2022): 349. https://doi.org/10.1080/14756366.2021.2015344.

MLA (9th ed.) Citation

MM, Elbadawi, et al. "2-Arylquinolines as Novel Anticancer Agents with Dual EGFR/FAK Kinase Inhibitory Activity: Synthesis, Biological Evaluation, and Molecular Modelling Insights." Journal of Enzyme Inhibition and Medicinal Chemistry, vol. 37, no. 1, 2022, p. 349, https://doi.org/10.1080/14756366.2021.2015344.